IXICO PLC (AIM:IXI, OTC:PHYOF) said it has won a £700,000 contract to provide MRI imaging services for patient selection and efficacy analysis for a phase 1/2 trial in people with a rare form of dementia.
The trial deploys an innovative gene therapy approach and is expected to last for just over four years, IXICO added.
Giulio Cerroni, chief executive, said he was delighted with the award of the contract.
“It is great to see our IXIQ.Ai advanced analytics technology being chosen by new clients to support patient eligibility assessment in innovative trial designs," he said.
“Deploying such approaches enables individual dosing decisions, paving the way towards personalised medicine."
Recently launched, the IXIQ.Ai platform enables the measurement of brain volumetry with increased sensitivity, compared to widely used tools.